Treace Medical beats FY22 revenue guidance; Q4 revenue up ~47-48% YoY

TREACE MEDICAL CONCEPTS, INC.

2022-FY EPS reported -$0.77 revenue$141,838,000

Preliminary Q4 2022 revenue $49.1M-$49.6M, up 47-48% YoY.
Preliminary FY22 revenue $141.2M-$141.7M, up ~50% YoY, above prior guidance of $135M-$138M.
CEO cites strength of direct sales channel, DTC programs, and R&D investments.
Company plans to provide 2023 guidance on Q4 earnings call.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TREACE MEDICAL CONCEPTS, INC. reported fourth quarter and full year 2022 results: revenue $49.1 to $49.6 million and $141.2 to $141.7 million, respectively.

Period: fourth quarter and full year 2022
Revenue: $49.1 to $49.6 million and $141.2 to $141.7 million, respectively
Result: preliminary results

Exact text from the filing

preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be in the range of $49.1 to $49.6 million and $141.2 to $141.7 million, respectively, representing an increase in the range of 47% to 48% and 50% over the same periods last year, respectively. The full

View on SEC.gov

Browse all earnings releases →

TREACE MEDICAL CONCEPTS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-000442

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.